The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE: ABT ) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older.
The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit.
Clinical Data And De Novo Pathway
The agency granted marketing authorization to Abbott via the De Novo pathway, which applies to new, low-to-moderate-risk medical devices.
The sensors alert users when ketones rise, replacing single-point urine or blood tests with continuous tracking.
Read Next NewsAbbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation
Abbott agreed to pay $670 million to resolve the Gill lawsuit and 2,000 other NEC claims involving its specialty preterm infant formulas.
2 min read Read this articleThis authorization followed a comprehensive review of six clinical studies involving over 600 participants. Trial results demonstrated the sensor accurately tracks clinically significant ketone variations.
Trending Get a 1% Match on Your First Deposit of $1,000+Libre Duo 10 Day offers up to 10 days of wear.
Future Integrations With Insulin Pumps
The manufacturer actively works with leading pump companies to connect the sensors with automated insulin delivery systems.
The company expects the Libre Duo 10 Day to sync with iLet from Beta Bionics Inc (NASDAQ: BBNX ) and twiist from Sequel Med Tech by the end of this year.
Looking ahead to 2027 , the dual monitor will integrate with systems from Insulet Corp (NASDAQ: PODD ) and Tandem Diabetes Care Inc. (NASDAQ: TNDM ). Additionally, the company is collaborating with MiniMed Group Inc. (NASDAQ: MMED ) on an exclusive integration for smart dosing systems expected the same year.
William Blair on Wednesday wrote, “Our initial impression of Abbott’s U.S. Libre Duo 10-day sensor clearance is that this sensor will likely be most competitive in the pediatric population once integrated with AID pumps into next year.
Analyst Brandon Vazquez also notes that the update may linger on DexCom Inc. (NASDAQ: DXCM ) shares as it creates a new competitive dynamic.
ABT Price Action: Abbott Laboratories shares were trading higher by 0.32% to $116.30 at the time of publication on Wednesday, according to Benzinga Pro data .
Read Next MarketsBitcoin Stuck Below $80,000 as Ethereum Funding Rates Hit 1-Year High
ETH funding rates hit 1-year high on Binance as BTC stalls below $80,000 due to profitable holders selling.
2 min read Read this articlePhoto: Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: News FDA General Top Stories Health Care Large Cap